Biotechnology

Panbela Therapeutics

Panbela Therapeutics released FY2024 cumulative Q3 earnings on November 14 After-Market (EST), with actual revenue of 0 and EPS of -5.2255

Panbela Therapeutics released FY2024 Q3 earnings on November 14 After-Market EST, with actual revenue of 0 USD (forecast 0 USD) and actual EPS of -1.4772 USD (forecast -1.21 USD)

Panbela Therapeutics to Release FY2024 Q3 Earnings on November 14 After-Market EST, Forecasted Revenue 0 USD, EPS -1.21 USD

Panbela Therapeutics, Inc. (OTCQB: PBLA) Announces Second Quarter Earnings Conference Call

Panbela Therapeutics Announces Third Independent Safety Review Passed

Panbela Therapeutics released FY2023 Cumulative 3Q Earnings on November 9 After-Market (EST), Revenue: 0, EPS: -605.6613

Panbela Therapeutics released FY2021 Q4 earnings on March 24 During-Market EST, with actual revenue of 0 and EPS of 0 (forecast EPS was -4.32 K)

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap